Reports of discussions between Ford Motor Company and Chinese tech giant Xiaomi over a potential electric vehicle partnership have ignited industry speculation, despite both firms denying any imminent deal. The talks underscore the complex interplay of technology, geopolitics, and market access shaping the global EV race.
In a bold marketing move, telehealth company Hims & Hers is leveraging the Super Bowl's massive audience to spotlight healthcare inequality with its 'Rich People Live Longer' campaign. The push comes as the company expands into advanced diagnostics and treatments, while its stock navigates a significant valuation gap after recent volatility.
Huntington Bancshares has finalized its merger with Cadence Bank, a move that significantly extends its regional footprint into Texas and the Southern U.S. and reshapes its competitive standing.
With one in twelve salaried employees having worked in multiple countries, Colgate-Palmolive is leveraging international assignments as a core strategy to build agile, globally-minded leadership.
Tyson Foods reported a 6.2% increase in Q1 2026 sales to $14.3 billion, driven by robust demand for protein. While the Chicken and Prepared Foods segments showed strength, the company is restructuring its Beef operations, closing one plant and scaling back another, to align with a constrained cattle supply outlook.
The parent company of Fatburger and Round Table Pizza, along with its Twin Hospitality spinoff, will be removed from the Nasdaq exchange effective February 4, transitioning to the over-the-counter market following Chapter 11 filings and over $1 billion in debt.
The Schwab U.S. Dividend Equity ETF (SCHD) offers investors a balanced approach to generating income, targeting financially robust companies with a history of growing dividends. We examine its strategy, performance, and role in a portfolio.
Piper Sandler raises its price target on Kura Sushi USA (KRUS) following an investor meeting, citing potential from recent changes to its digital loyalty platform. The company also appointed a new marketing-focused director as it eyes U.S. expansion.
While investors flock to mass-market and electric vehicle stocks, Ferrari's unique strategy of cultivating scarcity and brand prestige has delivered enviable margins and pricing power. With shares well off their highs, analysts debate if now is the time to buy into this iconic automaker for the long haul.
Stephens lowers price target on Cal-Maine Foods (CALM) citing near-term oversupply pressures, but the egg producer's long-term strategy remains focused on expanding its cage-free capacity through acquisition.
IDEXX Laboratories reports robust fourth-quarter and full-year 2025 results, with double-digit revenue growth fueled by record instrument placements and strategic innovations like InVue DX and CancerDx. The company provides a confident outlook for 2026, targeting continued organic growth despite sector headwinds.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
Aptiv PLC sees mixed but upwardly revised price targets from major analysts, with Piper Sandler upgrading the auto tech supplier to Overweight and naming it a top pick for 2026, citing its pragmatic strategy and attractive valuation.
Despite recent guidance revisions, Mobileye Global retains strong buy ratings from analysts who see significant upside potential, as the company positions 2026 for a strategic transition in the autonomous driving sector.
Disney CEO Bob Iger confirmed that AI-generated videos from OpenAI's Sora will begin appearing on Disney+ within months, framing the move as an additive feature for short-form content while downplaying any ripple effects on the company's traditional film and TV pipeline.
Apis Capital's flagship fund, which surged 55% in 2025, spotlights clinical-stage biotech Celcuity in its latest investor letter, citing the company's novel platform for matching cancer patients with targeted therapies.
Disney CEO Bob Iger says the fierce competition for Warner Bros. Discovery highlights the 'tremendous value' of Disney's existing franchises, while reaffirming the company's focus on organic IP creation over further major acquisitions.
Twist Bioscience kicks off fiscal 2026 with robust growth, reporting a 17% year-over-year revenue increase to $103.7 million. The company credits its semiconductor-based DNA synthesis platform and surging demand from AI-enabled drug discovery programs as key drivers, while reiterating its path to adjusted EBITDA breakeven within the year.
The Walt Disney Company surpassed Wall Street's revenue and earnings expectations for its fiscal first quarter, powered by strength in its streaming services and theme parks. The media giant reaffirmed its full-year forecast for double-digit profit growth, signaling confidence in its ongoing strategic transformation.
Investment firm Ashva Capital Management outlines its investment case for The Walt Disney Company in its Q4 2025 letter, highlighting the entertainment giant's enduring value proposition amid near-term market volatility.
